John C Chrystal, a director at $GEN, bought 10,000 shares of the company on 08-13-2025 for an estimated $321,000. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 344.7%. Following this trade, they now own 12,901 shares of this class of $GEN stock.
$GEN Insider Trading Activity
$GEN insiders have traded $GEN stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $GEN stock by insiders over the last 6 months:
- BRYAN SEUK KO (CLO & Head Corp Aff) sold 41,084 shares for an estimated $1,314,688
- NORA DENZEL sold 31,646 shares for an estimated $910,138
- JOHN C CHRYSTAL purchased 10,000 shares for an estimated $321,000
- NATALIE MARIE DERSE (CFO) sold 989 shares for an estimated $27,434
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GEN Hedge Fund Activity
We have seen 349 institutional investors add shares of $GEN stock to their portfolio, and 346 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PACER ADVISORS, INC. removed 6,597,745 shares (-65.6%) from their portfolio in Q2 2025, for an estimated $193,973,703
- FMR LLC added 5,495,159 shares (+16.0%) to their portfolio in Q2 2025, for an estimated $161,557,674
- STARBOARD VALUE LP removed 4,186,099 shares (-23.9%) from their portfolio in Q2 2025, for an estimated $123,071,310
- AMUNDI added 3,150,651 shares (+273.3%) to their portfolio in Q2 2025, for an estimated $92,629,139
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,846,534 shares (-23.2%) from their portfolio in Q2 2025, for an estimated $83,688,099
- NUVEEN, LLC added 2,787,922 shares (+24.7%) to their portfolio in Q2 2025, for an estimated $81,964,906
- ALYESKA INVESTMENT GROUP, L.P. removed 2,686,028 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $78,969,223
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GEN Congressional Stock Trading
Members of Congress have traded $GEN stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $GEN stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 04/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$GEN Analyst Ratings
Wall Street analysts have issued reports on $GEN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 08/08/2025
- Evercore ISI Group issued a "Outperform" rating on 07/01/2025
To track analyst ratings and price targets for $GEN, check out Quiver Quantitative's $GEN forecast page.
$GEN Price Targets
Multiple analysts have issued price targets for $GEN recently. We have seen 6 analysts offer price targets for $GEN in the last 6 months, with a median target of $34.0.
Here are some recent targets:
- Saket Kalia from Barclays set a target price of $33.0 on 08/08/2025
- Matthew Hedberg from RBC Capital set a target price of $33.0 on 08/08/2025
- Andrew Nowinski from Wells Fargo set a target price of $40.0 on 08/08/2025
- Hal Goetsch from B. Riley Securities set a target price of $46.0 on 07/14/2025
- Robert Coolbrith from Evercore ISI Group set a target price of $35.0 on 07/01/2025
- Hamza Fodderwala from Morgan Stanley set a target price of $25.0 on 04/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
